



Fusaramin, an antimitchondrial compound produced by *Fusarium* sp., discovered using multidrug-sensitive *Saccharomyces cerevisiae*

Katsuyuki Sakai¹ · Yufu Unten² · Masato Iwatsuki^{1,3} · Hiroataka Matsuo³ · Wataru Fukasawa¹ · Tomoyasu Hirose^{1,3} · Takumi Chinen⁴ · Kenichi Nonaka^{1,3} · Takuji Nakashima³ · Toshiaki Sunazuka^{1,3} · Takeo Usui⁴ · Masatoshi Murai² · Hideto Miyoshi² · Yukihiko Asami^{1,3} · Satoshi Ōmura³ · Kazuro Shiomi^{1,3}

Received: 14 March 2019 / Revised: 7 May 2019 / Accepted: 13 May 2019 / Published online: 17 June 2019
© The Author(s), under exclusive licence to the Japan Antibiotics Research Association 2019

Abstract

A new compound, fusaramin (**1**), along with three known compounds, sambutoxin (**2**), *N*-demethylsambutoxin (**3**) and (–)-6-deoxyoxysporidinone (**4**), was isolated from a culture broth of *Fusarium* sp. FKI-7550 by bioassay-guided fractionation using multidrug-sensitive *Saccharomyces cerevisiae* 12geneΔOHSR-iERG6. The chemical structure of **1** was elucidated by NMR studies and electronic circular dichroism spectrum. Compound **1** showed antibacterial activity against some Gram-positive and Gram-negative bacteria and inhibited the growth of *S. cerevisiae* 12geneΔOHSR-iERG6 grown on glycerol-containing medium. The MICs of **1** against wild-type and multidrug-sensitive yeasts grown on glycerol-containing medium were >128 μg ml⁻¹ and 0.64 μg ml⁻¹, respectively. However, MICs of **1** against both yeast strains grown on glucose-containing medium were >128 μg ml⁻¹. All compounds showed inhibition of ATP synthesis via oxidative phosphorylation using isolated *S. cerevisiae* mitochondria.

Introduction

Secondary metabolites produced by microorganisms display chemical diversity and have been used for a wide variety of purposes, including drugs and pesticides. Such important drugs derived from natural products as streptomycin,

adriamycin, pravastatin, FK506 and amphotericin B, have been clinically used following the discovery of penicillin by Fleming in 1928. Compounds derived from natural products also play an important role in pesticides, and some inhibitors of mitochondrial electron transport chain have been commercially available [1, 2]. In addition, a research group has reported a clinical-grade small-molecule inhibitor of complex I of the mitochondrial electron transport chain for a tumour inhibitor [3]. Therefore, inhibitors of mitochondrial electron transport chains may help increase yields in agriculture and be useful in human cancer chemotherapy. Therefore we undertook a programme to search for new mitochondrial inhibitors from microbial secondary metabolites, using a yeast screening system.

The budding yeast *Saccharomyces cerevisiae* is a useful tool for identification and evaluation of the targets of bioactive compounds. However, the high-level drug resistance of *S. cerevisiae* often makes the discovery of useful bioactive compounds difficult. An important factor in some resistance mechanisms is the ATP-binding cassette (ABC) transporter family that exports compounds from cells. Therefore, using the budding yeast system and examining expression of the transporter, we expected to find bioactive compounds that were undetectable using previous methods [4]. We exploited the multidrug-

Supplementary information The online version of this article (<https://doi.org/10.1038/s41429-019-0197-5>) contains supplementary material, which is available to authorized users.

✉ Satoshi Ōmura
omuras@insti.kitasato-u.ac.jp

✉ Kazuro Shiomi
shiomi@lisci.kitasato-u.ac.jp

¹ Graduate School of Infection Control Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

² Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa Oiwake-cho, Sakyo-ku, Kyoto 606-8502, Japan

³ Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan

⁴ Graduate School of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8572, Japan

sensitive budding yeast *12geneΔ0HSR-iERG6* strain [5] where 12 genes related to ABC transporters had been destroyed. We selected microbial culture broths that showed growth inhibition against the drug-sensitive *12geneΔ0HSR-iERG6* only on glycerol-containing medium (YPG agar medium; 1% yeast extract, 2% peptone, 3% glycerol and 1.5% agar) but which did not cause growth inhibition on glucose-containing medium (YPD agar medium; 1% yeast extract, 2% peptone, 3% glucose and 1.5% agar). Some compounds active against mitochondrial functions have been isolated by this method using glycerol- or glucose-containing medium [4, 6].

The screening system led to the discovery that *Fusarium* sp. FKI-7550 produced a new tetramic acid derivative (fusaramin, **1**) and three known compounds, sambutoxin [7] (**2**), *N*-demethylsambutoxin [8] (**3**) and (–)-6-deoxyoxysporidinone [9] (**4**) (Fig. 1). Here, we report the fermentation, isolation, structure elucidation and biological profiles of **1–4**.

Results

Structure elucidation of fusaramin (**1**)

The molecular formula of **1** was elucidated as $C_{27}H_{39}NO_4$ by HR-ESI-MS data ($[M + H]^+$, m/z 442.2946: calculated for $C_{27}H_{40}NO_4$, 442.2957), requiring nine degrees of unsaturation. All connections for 1H and ^{13}C in **1** were elucidated by HSQC study. The NMR data measured in $DMSO-d_6$ and the molecular formula indicated the presence of five methyls, five methylenes, five sp^3 methines including one oxygenated and one nitrogenated methine, six sp^2 methines and six fully-substituted sp^2 carbons (Table 1). 1H – 1H COSY of **1** indicated alignments from H_2 -7 (δ_H 2.54 and 2.63) to H_2 -10 (δ_H 1.65 and 1.90) and from H -12 (δ_H 4.83) to H_3 -17 (δ_H 0.79), plus connections between H -9 (δ_H 1.50) and H_3 -18 (δ_H 0.73), H -13 (δ_H 2.39) and H_3 -20 (δ_H 0.83), H -15 (δ_H 1.29) and H_3 -21 (δ_H 0.79) and H -5 (δ_H 4.17) and H -22 (δ_H 4.94) as shown in Fig. 2. The HMBC correlations from H_2 -10 to C -11 (δ_C 131.1), C -12 (δ_C 133.1) and C -19 (δ_C 15.7), from H -12 to C -10 (δ_C 47.0) and C -19 and from H_3 -19 (δ_H 1.49) to C -10, C -11 and C -12 suggested the alignment of C -10, C -11, C -12 and C -19. 1H , ^{13}C and 2D NMR data suggested that **1** has a phenyl group, and the HMBC correlations from phenyl protons (δ_H 7.16–7.22) to C -22 (δ_C 72.8) and from H -22 to phenyl carbons (δ_C 139.5 and 127.0) deduced the connection between C -22 and the phenyl group. Moreover, six remaining ^{13}C broad signals of **1** at δ_C 175.1 (C -2), 101.3 (C -3), 192.9 (C -4), 67.4 (C -5) and 188.7 (C -6) (Fig. S2) were assigned as a tetramic acid moiety after comparing with other tetramic acids [10–13]. It was





Fig. 1 Structures of fusaramin (**1**), sambutoxin (**2**), *N*-demethylsambutoxin (**3**) and (–)-6-deoxyoxysporidinone (**4**)

supported by four remaining degrees of unsaturation. Due to the tautomerism of tetramic acid, the ^{13}C signals of C -2 to C -6 were suggested to be broad. The HMBC correlations from H_2 -7 to C -3 and C -6 and from H_2 -8 (δ_H 1.15 and 1.39) to C -6 indicated the alignment of C -3, C -6 and C -7. Finally, the planar structure of **1** was elucidated by the HMBC correlations from H -5 to C -2, C -4 and C -23 and from H -22 to C -4. Furthermore, the geometry of a double bond between C -11 and C -12 was elucidated as being (*E*)-configuration by the NOESY cross peak between H_2 -10 and H -12 (Fig. 2). The relative configuration of C -5 and C -22 was elucidated as $5S^*$ and $22S^*$ by large 3J coupling constant of 7.2 Hz at H -5/ H -22 in **1** (in $CDCl_3$, Table S1) compared with the previous study [12] of tetramic acids, F-14329 and chaunolidines A–C. The absolute configuration of C -5 was elucidated as $5S$ by negative cotton effects at 226 and 285 nm in ECD spectra of **1** (in MeOH, Fig. S18) compared with the previous study [12]. Thus, the absolute configurations of **1** were elucidated to be $5S$ and $22S$.

Table 1 NMR spectroscopic data for fusaramin (**1**) in DMSO-*d*₆

Position	δ_C	Mult.	δ_H (int., mult., <i>J</i> in Hz)	HMBC
2	175.1	C		
3	101.3	C		
4	192.9	C		
5	67.4	CH	4.17 (1H, br s)	C-2, C-4, C-22, C-23
6	188.7	C		
7	30.7	CH ₂	2.54 (1H, m) 2.63 (1H, m)	C-3, C-6, C-8, C-9
8	32.3	CH ₂	1.15 ^a (1H, m) 1.39 (1H, m)	C-6, C-7, C-9, C-10, C-18
9	30.0	CH	1.50 (1H, m)	C-8, C-10, C-18
10	47.0	CH ₂	1.65 (1H, dd, <i>J</i> = 7.2, 12.9 Hz) 1.90 (1H, dd, <i>J</i> = 7.2, 12.9 Hz)	C-8, C-9, C-11, C-12, C-18, C-19
11	131.1	C		
12	133.1	CH	4.83 (1H, d, <i>J</i> = 9.6 Hz)	C-10, C-13, C-14, C-19, C-20
13	29.4	CH	2.39 (1H, m)	C-11, C-12, C-14, C-15, C-20
14	44.6	CH ₂	0.99 ^b (1H, m) 1.15 ^a (1H, m)	C-12, C-15, C-16, C-20, C-21
15	31.5	CH	1.29 ^c (1H, m)	C-14, C-16, C-17, C-21
16	28.4	CH ₂	1.00 ^b (1H, m) 1.32 ^c (1H, m)	C-14, C-15, C-17, C-21
17	11.1	CH ₃	0.79 (3H, t, <i>J</i> = 7.5 Hz)	C-15, C-16
18	18.7	CH ₃	0.73 (3H, d, <i>J</i> = 6.6 Hz)	C-8, C-9, C-10
19	15.7	CH ₃	1.49 (3H, br s)	C-10, C-11, C-12
20	21.2	CH ₃	0.83 (3H, d, <i>J</i> = 6.6 Hz)	C-12, C-13, C-14
21	19.5	CH ₃	0.79 (3H, d, <i>J</i> = 6.6 Hz)	C-14, C-15, C-16
22	72.8	CH	4.94 (1H, br s)	C-4, C-5, C-23, C-24/28
23	139.5	C		
24/28	127.0	CH	7.16–7.22 (2H, m)	
25/27	127.3	CH	7.16–7.22 (2H, m)	
26	127.2	CH	7.16–7.22 (1H, m)	
1		NH	8.88 ^d (1H, br s)	
6		OH	5.96 ^d (1H, br s)	
22		OH	5.96 ^d (1H, br s)	

Data were collected at 600 MHz for ¹H and 150 MHz for ¹³C^{a,b,c}Overlapped^dExchangable**Fig. 2** Structure elucidation of fusaramin (**1**). ¹H–¹H COSY (bold lines), key HMBC (arrows) and key NOESY correlation (dashed arrow)

Evaluation of antimicrobial activity of fusaramin (**1**) by the agar diffusion method

The antimicrobial activities of **1** were evaluated by the agar diffusion method using some Gram-positive and Gram-negative bacteria, yeasts (including *Candida albicans* and wild-type and multidrug-sensitive budding yeast *S. cerevisiae*) and a filamentous fungus (*Mucor racemosus*). The result of antimicrobial evaluation is shown in Table S2. Compound **1** showed growth inhibition against some Gram-positive bacteria (*Staphylococcus aureus*, *Bacillus subtilis* and *Kocuria rhizophila*) and one Gram-negative bacterium (*Xanthomonas oryzae* pv. *oryzae*). Although **1** did not exhibit growth inhibition against wild-type *S. cerevisiae* KF237 and BY4741, *S. cerevisiae* BY25929, *C. albicans* FK1 and multidrug-sensitive *S. cerevisiae* 12geneΔOHSR-iERG6 grown on YPD agar medium, it inhibited the growth of *S. cerevisiae* 12geneΔOHSR-iERG6 on YPG agar medium. As **1** inhibited yeast growth only in glycerol medium, which is similar to mitochondrial respiration inhibitors, such as ascosteroside C [6], trichopolyn VI [14] and decatamariic acid [4], we hypothesized that **1** might inhibit mitochondrial functions.

Evaluation of MIC values of 1–4 against yeasts

We measured the minimum inhibition concentrations (MICs) of **1–4** against wild-type and multidrug-sensitive *S. cerevisiae* (Table 2). All compounds did not demonstrate any inhibition against the wild-type yeast grown on YPD medium, and **4** slightly inhibited the multidrug-sensitive yeast grown on YPD medium. It is interesting that all compounds showed strong inhibition against the multidrug-sensitive yeast grown on YPG medium. Compound **2** was reported to be an inhibitor of electron transfer of quinol-cytochrome *c* oxidoreductase (complex III) [15] and showed >2000-fold more potent growth inhibition against multidrug-sensitive *S. cerevisiae* growth on YPG medium than on YPD medium. The selectivity of **1**, **3** and **4** was >200, >400 and 16 times, respectively. Therefore, we

Table 2 MICs of 1–4 against yeasts

Compound	MICs ($\mu\text{g ml}^{-1}$)			
	BY4741		12gene Δ OHSR-iERG6	
	YPD	YPG	YPD	YPG
1	>128	>128	>128	0.64
2	>128	4	>128	0.064
3	>128	>128	>128	0.32
4	>128	>128	32	2.0

assumed that the target of 1–4 is any one of the mitochondrial functions, such as the electron transfer system. As most of the compounds did not show growth inhibition against the wild-type yeast, it is strongly suggested that the multidrug-sensitive budding yeast is a useful tool to find new growth inhibition compounds.

Evaluation of inhibition of mitochondrial functions

With the assay monitoring overall ADP-uptake/ATP-release reactions [16], using mitochondria (respiring with α -ketoglutarate) isolated from wild-type *S. cerevisiae*, we evaluated the inhibitory effects of 1–4 on mitochondrial functions. This assay method principally enabled us to determine potential inhibitors of any of the mitochondrial mechanisms presiding over ATP synthesis via oxidative phosphorylation. Compounds 1–4 inhibited overall ADP-uptake/ATP-release reactions; the IC_{50} (the molar concentration required for 50% inhibition) are listed in Table 3. Of the four compounds, 2 turned out to be the most potent.

To know whether the compounds inhibit ATP synthesis by acting on the electron transfer system, we examined their effects on the NADH-cytochrome *c* oxidoreductase activity [17] (covering NADH dehydrogenase to complex III). The concentrations of 1–4 were set to 72, 2.6, 28 and 370 nmol/mg of proteins, respectively, equivalent to $3 \times \text{IC}_{50}$ obtained in the above ADP-uptake/ATP-release reactions (Table 3). Compounds 2–4, but not 1, significantly inhibited NADH-cytochrome *c* oxidoreductase activity (Fig. 3), indicating that 2–4 are inhibitors of complex III, as reported previously [15]. The potential target of 1 may be one of the transporters of substrates that are essential for ATP synthesis, such as an ADP/ATP carrier (though we have not yet identified the target).

Cytotoxic evaluation

We tested the cytotoxic activity of compounds 1–4 against various cancer cell lines (floating cell lines, HL-60, Jurkat and THP-1; adherent cell lines, HeLa S3, HT29, A549, H1299 and Panc1). Compound 4 showed cytotoxic against both floating and adherent cell lines. Compounds 1, 2 and 3

Table 3 IC_{50} of 1–4 in overall ADP-uptake/ATP-release reactions with isolated yeast mitochondria

Compound	IC_{50} (μM) ^a
1	1.2 ± 0.25
2	0.042 ± 0.0046
3	0.44 ± 0.070
4	5.9 ± 1.7

^aValues are means \pm standard error




Fig. 3 Effects of 1–4 on the electron transfer system in yeast mitochondria. Isolated yeast mitochondria were permeabilized by repeated freeze-thawing under N_2 atmosphere and the NADH-cytochrome *c* oxidoreductase activity was measured in the presence of 1–4, as described in the experimental procedures. The concentrations of 1–4 were set to 72, 2.6, 28 and 370 nmol/mg of proteins, respectively, which are equivalent to $3 \times \text{IC}_{50}$ that was obtained in the ADP-uptake/ATP-release reactions (Table 3). Values show means \pm S.E.M. ($n = 3$)

exhibited potent cytotoxicity against floating cell lines (Table 4).

Discussion

We isolated 1–4 using an *S. cerevisiae* 12gene Δ OHSR-iERG6 obtained from the culture broth of *Fusarium* sp. FKI-7550.

Compound 1 is a tetramic acid derivative composed of an aromatic amino acid and a polyketide. These types of compounds are produced by fungi, such as epicoccarines A and B, F-14329, chaunolidines A and B, militarinone B, tolypoalbin and pretenellin A [10, 12, 13, 18]. Among them, militarinone B and pretenellin A are co-produced with militarinone A and tenellin, respectively, which have a pyridone-type rearranged ring. Biosynthesis study of tenellin revealed that pretenellin A was a precursor of

Table 4 IC₅₀ of **1–4** of various cell lines

Compound	IC ₅₀ (μM)* of various cell lines							
	HL-60	Jurkat	THP-1	HeLa S3	HT29	A549	H1299	Panc1
1	1.9	5.8	3.0	57.1	34.4	38.4	64.4	>100
2	<1.0	<1.0	<1.0	5.1	14.6	15.8	10.7	>100
3	1.1	1.5	<1.0	15.0	18.2	16.8	17.7	16.8
4	7.8	16.4	13.0	15.7	18.3	60.9	19.9	16.6

*Staurosporine was used as a positive control (1 μg ml⁻¹)

tenellin [18]. Compound **1** may be a precursor of **2–4** based on their structural resemblance. Several tetramic acid derivatives composed of an aromatic amino acid and a polyketide have been reported, and their aromatic amino acid parts were tyrosine, β-hydroxytyrosine or phenylalanine. Compound **1** is the first compound having β-hydroxyphenylalanine as the aromatic amino acid part.

Evaluation of the growth inhibition of the yeast by **1** suggested that it may be an inhibitor of mitochondrial functions because this compound inhibited the growth of the multidrug-sensitive budding yeast *S. cerevisiae* 12geneΔOHSR-iERG6 grown on YPG agar medium but did not inhibit the yeast grown on YPD agar medium. The biochemical evaluation using isolated yeast mitochondria verified this notion. As for the cytotoxicity, **1** preferentially inhibited growth inhibition against floating cell lines, HL-60, Jurkat and THP-1 but did not show growth inhibition against adherent cell lines, HeLa S3, HT29, A549, H1299 and Panc1. Tetramic acid analogues have been reported to display antimicrobial, antitumor, antiviral and anti-mitochondrial activities [19, 20]. The inhibitions of tetramic acids on mitochondrial functions have previously only been reported for equisetin and equisetin-like compounds [20, 21], but the structure of **1** does not resemble equisetin. Further chemical and biological studies of **1** may lead to the development of a new type of mitochondrial inhibitor.

Experimental section

General experiments

Reverse- and normal-phase column chromatography was conducted on YMC-gel ODS-A (150 μm) and Silica gel 60 (0.063–0.200 mm), respectively. A Chromatorex C8 SPS100-5HE column was purchased from Fuji Silysia Chemical Co. (Aichi, Japan). High- and low-resolution mass data were measured on a JEOL JMS-T100LP (JEOL, Tokyo, Japan). NMR spectra were measured on a Bruker Avance III HD600 (Bruker Corp, Germany) with ¹H NMR at 600 MHz and ¹³C NMR at 125 MHz and on a Varian XL-400 spectrometer (Agilent Technologies, CA, USA) with ¹H NMR at 400 MHz and ¹³C NMR at 100 MHz in DMSO-

*d*₆ and CDCl₃. The chemical shifts were expressed in ppm and were referenced to DMSO-*d*₆ (2.48 ppm) and CDCl₃ (7.26 ppm) in the ¹H NMR spectra and DMSO-*d*₆ (39.5 ppm) and CDCl₃ (77.0 ppm) in the ¹³C NMR spectra.

IR spectra (ATR) were measured on an FT-210 Fourier transform IR spectrometer (Horiba Ltd, Kyoto, Japan). UV spectra were recorded on a Hitachi U-2801 spectrophotometer (Hitachi Ltd, Tokyo, Japan). Optical rotation was measured on a JASCO P-2200 polarimeter (JASCO Corporation, Tokyo, Japan). OD₆₀₀ was measured on a Corona Grating Microplate Reader SH-9000 (Corona Electric, Ibaraki, Japan). ECD spectra were measured on a J-720 (JASCO Corporation, Tokyo, Japan).

Taxonomic studies

Fungal strain FKI-7550 was isolated from soil around the root of *Cerasus × yedoensis* collected in Tokushima, Japan. This strain was identified with members of the genus *Fusarium* by its producing lunate to falcate macroconidia and ellipsoidal microconidia. The ITS sequence of strain FKI-7550 was compared to sequences in the GenBank database by BLASTN 2.7.1 analysis [22]. The sequence of FKI-7550 was 99.6% similar to that of NRRL 25181 (ex-type of *Fusarium concentricum*, GenBank accession number NR_111886). The producing strain FKI-7550 was assigned to the genus and was designated as *Fusarium* sp. based on its morphology and sequence analysis.

Fermentation

One loopful of strain FKI-7550 grown on an LcA slant (0.1% glycerol, 0.08% KH₂PO₄, 0.02% K₂HPO₄, 0.02% MgSO₄·7 H₂O, 0.02% KCl, 0.2% NaNO₃, and 1.5% agar, pH 6.0) was inoculated into a 500-ml Erlenmeyer flask containing 100 ml of a seed culture medium [2% glucose, 0.2% yeast extract, 0.05% MgSO₄·7 H₂O, 0.5% Polypepton (Wako Pure Chemical Industries, Ltd), 0.1% KH₂PO₄, and 0.1% agar, pH 6.0 and incubated on a rotary shaker at 27 °C for 4 days. Twenty-five millilitres of the seed culture was inoculated into each of 200 Ulpack 47 culture bags (Hokken Co. Ltd, Tochigi, Japan) containing a production medium

(500 g of water-sodden rice). Static fermentation was continued at 27 °C for 12 days.

Isolation and identification of 1–4

The stationary culture was extracted with acetone (120 l) and the extract was filtrated. The filtrate was concentrated in vacuo to remove acetone. The remaining aqueous solution (35 l) was extracted three times with an equal volume of EtOAc (total 105 l). The organic layer was concentrated to dryness to afford a crude extract (628 g). The extract was chromatographed on a Diaion HP20 column and eluted stepwise with a mixture of MeOH–H₂O (20:80, 50:50 and 100:0). Compounds were eluted with the 100:0 eluate, and the solution was concentrated in vacuo to remove MeOH. The 100:0 fraction (129 g) was applied to an ODS gel column (55 i.d. × 215 mm) and eluted stepwise with a mixture of MeOH–H₂O (20:80, 50:50, 70:30, 80:20, 90:10 and 100:0). The 80:20 fraction was concentrated to dryness to afford a crude extract (33 g). The extract was chromatographed on a silica gel column and eluted stepwise with a mixture of CHCl₃–MeOH (100:0, 100:1, 100:5, 90:10, 1:1 and 0:100). The active fraction (90:10) was concentrated in vacuo to remove organic solvent. Finally, the concentrated material (1.6 g) was applied to an HPLC (Chromatorex C8 SPS100-5HE, 20 i.d. × 250 mm) with an isocratic solvent system of 70% acetonitrile–water with 0.1% trifluoroacetic acid solution at a flow rate of 10 ml min⁻¹ to give the new compound (34.4 mg), fusaramin (**1**).

The active fraction (100:5) from silica gel column chromatography (0.6 g) was applied to an HPLC (Chromatorex C8 SPS100-5HE, 20 i.d. × 250 mm) with an isocratic solvent system of 65% acetonitrile–water with 0.1% trifluoroacetic acid solution at a flow rate of 10 ml min⁻¹ to give active peaks at 33–35 and 45–48 min. The peak of 45–48 min was identified as sambutoxin (33.9 mg, **2**) using ESI-MS data and NMR data. The peak of 33–35 min (35.5 mg) was further applied to an HPLC (Chromatorex C8 SPS100-5HE, 20 i.d. × 250 mm) with an isocratic solvent system of 55% acetonitrile–water with 0.1% trifluoroacetic acid solution at a flow rate of 10 ml min⁻¹ to give (–)-6-deoxyoxysporidinone (12.6 mg; retention time 72–79 min; **4**) and *N*-demethylsambutoxin (13.6 mg; retention time 81–91 min; **3**).

Fusaramin (1): yellow oil; soluble in DMSO, MeOH, acetone and CHCl₃; insoluble in H₂O; [α]_D²⁵ –127.2 (*c* = 0.1, MeOH); IR ν_{\max} (ATR) cm⁻¹ 3332, 2954, 2919, 1650, 1596, 1450, 1342, 1106 and 1041; UV (MeOH) λ_{\max} (ϵ) 203 (20 100), 242 (8500) and 281 (13 100) nm; CD (MeOH) λ_{\max} ($\Delta\epsilon$) 226 (–18 412), 242 (–10 585), 262 (–9472) and 285 (–9759) nm. ¹H and ¹³C NMR data are shown in Table 1.

Sambutoxin (2): yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 10.08 (–OH, br s), 7.24 (2H, d, *J* = 8.4 Hz), 7.12 (1H, s), 6.29 (2H, d, *J* = 8.8 Hz), 5.18 (1H, d, *J* = 9.2 Hz), 5.04 (1H, dd, *J* = 11.0, 1.8 Hz), 3.51 (1H, m), 3.51 (3H, s), 2.46 (1H, m), 2.07 (1H, d, *J* = 13.6 Hz), 1.89 (1H, m), 1.71–1.58 (2H, overlapped), 1.61 (3H, s), 1.45–1.16 (4H, overlapped), 1.03 (2H, m), 0.89 (3H, d, *J* = 6.8 Hz), 0.82 (3H, t, *J* = 7.2 Hz), 0.82 (3H, d, *J* = 6.4 Hz) and 0.73 (3H, d, *J* = 6.8 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 162.7, 161.3, 156.5, 138.0, 135.9, 130.2, 130.2, 130.0, 124.8, 116.0, 115.4, 115.4, 110.4, 92.5, 77.6, 44.6, 37.4, 32.2, 32.0, 31.9, 30.6, 29.5, 28.8, 20.6, 19.5, 17.5, 11.5 and 11.1; ESI-MS (+) mode *m/z* 454 [M + H]⁺ and ESI-MS (–) mode *m/z* 452 [M – H][–]. The NMR and MS data showed good correlation with those of sambutoxin [7].

***N*-Demethylsambutoxin (3)**: pale yellow oil; ¹H NMR (400 MHz, CDCl₃) δ 10.25 (–OH, s), 7.16 (2H, d, *J* = 8.4 Hz), 6.95 (2H, d, *J* = 8.8 Hz), 6.64 (1H, s), 5.21 (1H, d, *J* = 13.2 Hz), 5.05 (1H, d, *J* = 12.0 Hz), 3.55 (1H, d, *J* = 9.6 Hz), 2.46 (1H, m), 2.07 (1H, m), 1.91 (1H, d, *J* = 10.8 Hz), 1.68 (1H, m), 1.62 (3H, s), 1.62 (1H, m), 1.46–1.17 (4H, overlapped), 1.04 (2H, m), 0.90 (3H, d, *J* = 6.4 Hz), 0.83 (3H, t, *J* = 7.2 Hz), 0.82 (3H, d, *J* = 6.0 Hz) and 0.74 (3H, d, *J* = 6.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 164.4, 163.4, 156.6, 138.2, 132.8, 130.5, 130.5, 130.0, 125.2, 116.6, 115.6, 115.6, 110.1, 92.7, 77.2, 44.7, 32.3, 31.9, 31.9, 31.0, 29.6, 28.8, 20.6, 19.6, 17.5, 11.6 and 11.2; ESI-MS (+) mode *m/z* 440 [M + H]⁺ and ESI-MS (–) mode *m/z* 438 [M – H][–]. These data showed good correlation with those of *N*-demethylsambutoxin [8].

(–)-6-Deoxyoxysporidinone (4): pale yellow oil; [α]_D²³ –100.5 (*c* = 0.1, MeOH); ¹H NMR (400 MHz, CDCl₃) δ 10.49 (–OH, br s), 7.14 (1H, s), 5.20 (1H, d, *J* = 9.2 Hz), 4.94 (1H, d, *J* = 10.8 Hz), 3.50 (1H, d, *J* = 10.0 Hz), 3.44 (3H, s), 2.89 (2H, m), 2.48 (1H, m), 2.36–2.03 (8H, overlapped), 1.89 (1H, m), 1.68 (1H, m), 1.65 (3H, s), 1.44–1.17 (4H, overlapped), 1.04 (2H, m), 0.91 (3H, d, *J* = 6.8 Hz), 0.83 (6H, overlapped), 0.74 (3H, d, *J* = 6.4 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 211.7, 162.1, 161.1, 138.1, 133.2, 129.9, 117.5, 111.1, 92.4, 78.0, 70.2, 44.6, 37.2, 36.8, 36.8, 36.1, 36.0, 32.4, 31.9, 31.9, 30.6, 29.6, 28.8, 20.6, 19.5, 17.5, 11.8 and 11.1; ESI-MS (+) mode *m/z* 496 [M + Na]⁺ and ESI-MS (–) mode *m/z* 472 [M – H][–]. These data showed good correlation with those of (–)-6-deoxyoxysporidinone [9].

Evaluation of antimicrobial activity using the agar diffusion method

All of evaluation was performed by the paper disc method [4] using 6 mm discs.

Evaluation of MIC values of 1–4

We evaluated the MIC of each compound against yeasts using a broth microdilution method [23]. The test compounds were dissolved in MeOH. The yeasts (1.0×10^4 cells/100 μ l/well in a 96-well plate) were cultured in either YPD or YPG liquid medium with $1 \times 10^{-4}\%$ TWEEN 20 (Sigma-Aldrich, Co., St. Louis, USA) in the presence of various concentrations of 1–4 for 2 and 3 days, respectively. MICs were evaluated by measuring OD₆₀₀ on a Corona Grating Microplate Reader SH-9000 (Corona Electric, Ibaraki, Japan).

Evaluation of the inhibition of ADP-uptake/ATP-release in isolated mitochondria

The measurement of ADP-uptake/ATP-release in isolated mitochondria was performed according to the method reported by Lousa et al. [16]. Isolated mitochondria (50 μ g of proteins/ml) were suspended in 2.5 ml of reaction buffer (0.60 M mannitol, 0.10 mM EGTA, 2.0 mM MgCl₂, 10 mM KP_i, 5.0 mM α -ketoglutarate, and 10 mM Tris-HCl, pH 7.4) at 30 °C in the presence of an ATP detecting system (2.5 mM glucose, hexokinase (1.7 E.U.), glucose-6-phosphate dehydrogenase (0.85 E.U.), 0.20 mM NADP⁺ and 10 μ M Ap₅A). Externally added ADP (25 mM) initiated exchange reaction with ATP synthesized in mitochondrial matrix. The formation of NADPH, which is proportional to ATP efflux, was measured continuously for 10 min spectrophotometrically on a Shimadzu UV3000 (340 nm; $\epsilon = 6.2 \text{ mM}^{-1} \text{ cm}^{-1}$).

Evaluation of NADH-cytochrome c oxidoreductase activity

Isolated yeast mitochondria were permeabilized by repeated freeze-thawing in 50 mM KP_i buffer (pH 7.4) to improve the accessibility of substrates (NADH and cytochrome *c*). The NADH-cytochrome *c* oxidoreductase activity was followed by the reduction of cytochrome *c* (550–540 nm; $\epsilon = 21 \text{ mM}^{-1} \text{ cm}^{-1}$) in buffer (2.5 ml) containing 50 mM KP_i (pH 7.4), 4.0 mM KCN and 50 μ M cytochrome *c* (from horse heart, Sigma-Aldrich) at 30 °C. Protein concentration was set to 12 μ g ml⁻¹, and the reaction was initiated by the addition of NADH (the final concentration of 50 μ M).

Cytotoxic evaluation

Cytotoxicity of 1–4 was evaluated using three floating cell lines, HL-60 (human promyelocytic leukaemia cell line), Jurkat (human acute lymphocytic leukaemia cell line) and THP-1 (human acute monocytic leukaemia cell line), along with five adherent cell lines, HeLa S3 (human cervical

cancer cell line), HT29 (human colorectal adenocarcinoma cell line), A549 (human adenocarcinoma cell line derived from lung cancer), H1299 (human non-small cell lung carcinoma cell line derived from lymph nodes) and Panc1 (human cell line derived from pancreatic cancer).

Culture conditions were as follows: floating cell lines [RPMI medium (Nacalai Tesque, Inc, Kyoto, Japan) added to 10% FBS, 1% sodium pyruvate and 1% penicillin streptomycin, 37 °C, under 5% CO₂] and adherent cell lines [DMEM medium (Wako Pure Chemical Industries, Osaka, Japan) added to 10% FBS and 1% penicillin streptomycin, 37 °C, under 5% CO₂].

The cultivated floating (3×10^5 cells per well) and adherent (5×10^3 cells per well) cell lines were seeded in 96-well plates. After culturing overnight, MeOH solutions of 1–4 were added into each well. After 2 days of incubation at 37 °C, WST-8 solution was added to each well and kept for 4 h at 37 °C. The absorbance of each well was measured on a Corona Grating Microplate Reader SH-9000 at 460 nm.

Acknowledgements This research was supported financially by The Public Foundation of Elizabeth Arnold-Fuji, Japan. We are grateful to Dr Kenichiro Nagai and Ms Noriko Sato, School of Pharmacy, Kitasato University, for help in obtaining NMR and MS data.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

- Balba H. Review of strobilurin fungicide chemicals. *J Environ Sci Health B*. 2007;42:441–51.
- Eisinger M, Almog Y. Primidifen intoxication. *Ann Emerg Med*. 2003;42:289–91.
- Molina JR, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. *Nat Med*. 2018;24:1036–46.
- Watanabe Y, et al. Decatamariic acid, a new mitochondrial respiration inhibitor discovered by pesticidal screening using drug-sensitive *Saccharomyces cerevisiae*. *J Antibiot*. 2017;70:395–9.
- Chinen T, Nagumo Y, Usui T. Construction of a genetic analysis-available multidrug sensitive yeast strain by disruption of the drug efflux system and conditional repression of the membrane barrier system. *J Gen Appl Microbiol*. 2014;60:160–2.
- Suga T, et al. Ascosteroside C, a new mitochondrial respiration inhibitor discovered by pesticidal screening using recombinant *Saccharomyces cerevisiae*. *J Antibiot*. 2015;68:649–52.
- Kim JC, Lee YW, Tamura H, Yoshizawa T. Sambutoxin: a new mycotoxin isolated from *Fusarium sambucinum*. *Tetrahedron Lett*. 1995;36:1047–50.
- Jayasinghe L, Abbas HK, Jacob MR, Herath WH, Nanayakkara NP. *N*-Methyl-4-hydroxy-2-pyridinone analogues from *Fusarium oxysporum*. *J Nat Prod*. 2006;69:439–42.

9. Zhan J, Burns AM, Liu MX, Faeth SH, Gunatilaka AA. Search for cell motility and angiogenesis inhibitors with potential anticancer activity: beauvericin and other constituents of two endophytic strains of *Fusarium oxysporum*. *J Nat Prod*. 2007;70:227–32.
10. Kemami Wangun HV, Hertweck C. Epicoccarines A, B and epipyridone: tetramic acids and pyridone alkaloids from an *Epicoecum* sp. associated with the tree fungus *Pholiota squarrosa*. *Org Biomol Chem*. 2007;5:1702–5.
11. Xu W, Cai X, Jung ME, Tang Y. Analysis of intact and dissected fungal polyketide synthase-nonribosomal peptide synthetase in vitro and in *Saccharomyces cerevisiae*. *J Am Chem Soc*. 2010;132:13604–7.
12. Shang Z, et al. New PKS-NRPS tetramic acids and pyridinone from an Australian marine-derived fungus, *Chaunopycnis* sp. *Org Biomol Chem*. 2015;13:7795–802.
13. Fukuda T, et al. Tolypoalbin, a new tetramic acid from *Tolypocladium album* TAMA 479. *J Antibiot*. 2015;68:399–402.
14. Suga T, et al. Trichopolyn VI: a new peptaibol insecticidal compound discovered using a recombinant *Saccharomyces cerevisiae* screening system. *J Gen Appl Microbiol*. 2015;61:82–7.
15. Kawai K, Suzuki T, Kitagawa A, Kim JC, Lee YW. A novel respiratory chain inhibitor, sambutoxin from *Fusarium sambucinum*. *Cereal Res Commun*. 1997;25:325–6.
16. De Marcos Lousa C, Trézéguet V, Dianoux AC, Brandolin G, Lauquin GJ. The human mitochondrial ADP/ATP carriers: kinetic properties and biogenesis of wild-type and mutant proteins in the yeast *S. cerevisiae*. *Biochemistry*. 2002;41:14412–20.
17. Unten Y, et al. Pentendiol-type compounds specifically bind to voltage-dependent anion channel 1 in *Saccharomyces cerevisiae* mitochondria. *Biochemistry*. 2019;58:1141–54.
18. Halo L, et al. Late stage oxidations during the biosynthesis of the 2-pyridone tenellin in the entomopathogenic fungus *Beauveria bassiana*. *J Am Chem Soc*. 2008;130:17988–96.
19. Mo X, Li Q, Ju J. Naturally occurring tetramic acid products: isolation, structure elucidation and biological activity. *RSC Adv*. 2014;4:50566–93.
20. Quek NC, et al. The novel equisetin-like compound, TA-289, causes aberrant mitochondrial morphology which is independent of the production of reactive oxygen species in *Saccharomyces cerevisiae*. *Mol Biosyst*. 2013;9:2125–33.
21. Köning T, Kapus A, Sarkadi B. Effects of equisetin on rat liver mitochondria: evidence for inhibition of substrate anion carriers of the inner membrane. *J Bioenerg Biomembr*. 1993;25:537–45.
22. Altschul SF, et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Res*. 1997;25:3389–402.
23. Sakai K, et al. Pasticocandin, a new papulacandin class antibiotic isolated from *Pestalotiopsis humus*. *J Antibiot*. 2018;71:1031–5.